Treatment Initiation,Substance Use Trajectories,and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder
Restricted accessResearch articleFirst published online October, 2023
Treatment Initiation,Substance Use Trajectories,and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder
People living with HIV and opioid use disorder (OUD) are disproportionally affected by adverse socio-structural exposures negatively affecting health, which have shown inconsistent associations with uptake of medications for OUD (MOUD). This study aimed to determine whether social determinants of health (SDOH) were associated with MOUD uptake and trajectories of substance use in a clinical trial of people seeking treatment.
Methods:
Data are from a 2018 to 2019 randomized trial comparing the effectiveness of different MOUD to achieve viral suppression among people living with HIV and OUD. SDOH were defined by variables mapping to Healthy People 2030 domains: education (Education Access and Quality), income (Economic Stability), homelessness (Neighborhood and Built Environment), criminal justice involvement (Social and Community Context), and recent SUD care (Health Care Access and Quality). Associations between SDOH and MOUD initiation were assessed with Cox proportional hazards models, and SDOH and substance use over time with generalized estimating equation models.
Results:
Participants (N = 114) averaged 47 years old, 63% were male, 56% were Black, and 12% Hispanic. Participants reported an average of 2.3 out of 5 positive SDOH indicators (SD = 1.2). Stable housing was the most commonly reported SDOH (61%), followed by no recent criminal justice involvement (59%), having a high-school level education or greater (56%), income stability (45%), and recent SUD care (13%). Each additional favorable SDOH was associated with a 25% increase in the likelihood of MOUD initiation during the study period [adjusted HR = 1.25, 95% CI = (1.01, 1.55), P = .044]. Positive SDOH were also associated with a decrease in the odds of baseline opioid use and a greater reduction in opioid use during subsequent weeks of the study (P < .001 for a joint test of baseline and slope differences).
Conclusions:
Positive social determinants of health, in aggregate, may increase the likelihood of MOUD treatment initiation among people living with HIV and OUD.
TsuiJIAkosileMALaphamGT, et al. Prevalence and medication treatment of opioid use disorder among primary care patients with hepatitis C and HIV. J Gen Intern Med. 2021;36(4):930-937. doi:10.1007/s11606-020-06389-7
3.
ChangMHMoonesingheRSchieberLZTrumanBI.Opioid-related diagnoses and concurrent claims for HIV, HBV, or HCV among medicare beneficiaries, United States, 2015. J Clin Med. 2019;8(11):1768. doi:10.3390/jcm8111768
4.
SurrattHLO’GradyCLLevi-MinziMAKurtzSP.Medication adherence challenges among HIV positive substance abusers: the role of food and housing insecurity. AIDS Care. 2015;27(3):307-314. doi:10.1080/09540121.2014.967656
5.
DenisCMDominiqueTSmithP, et al. HIV infection and depression among opiate users in a US epicenter of the Opioid Epidemic. AIDS Behav. 2021;25(7):2230-2239. doi:10.1007/s10461-020-03151-2
6.
SulleySNdangaM.Inpatient opioid use disorder and social determinants of health: A nationwide analysis of the national inpatient sample (2012-2014 and 2016-2017). Cureus. 2020;12(11):e11311. doi:10.7759/cureus.11311
7.
CernasevAVeveMPCoryTJ, et al. Opioid use disorders in people living with HIV/AIDS: a review of implications for patient outcomes, drug interactions, and neurocognitive disorders. Pharmacy. 2020;8(3):168. doi:10.3390/pharmacy8030168
8.
SpringerSA.Ending the HIV epidemic for persons who use drugs: the practical challenges of meeting people where they are. J Gen Intern Med. 2023. doi:10.1007/s11606-023-08142-2
9.
BlueTRGordonMSSchwartzRP, et al. Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine. Addict Sci Clin Pract. 2019;14(1):45. doi:10.1186/s13722-019-0172-2
10.
HoffmanKAPonce TerashimaJMcCartyD.Opioid use disorder and treatment: challenges and opportunities. BMC Health Serv Res. 2019;19(1):884. doi:10.1186/s12913-019-4751-4
11.
MeyerJPAlthoffALAlticeFL.Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis. 2013;57(9):1309-1317. doi:10.1093/cid/cit427
12.
FanucchiLSpringerSAKorthuisPT.Medications for treatment of opioid use disorder among persons living with HIV. Curr HIV/AIDS Rep. 2019;16(1):1-6. doi:10.1007/s11904-019-00436-7
13.
WilliamsARNunesEVBisagaALevinFROlfsonM.Development of a cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1-10. doi:10.1080/00952990.2018.1546862
14.
MauroPMGutkindSAnnunziatoEMSamplesH.Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. JAMA netw open. 2022;5(3):e223821-e223821. doi:10.1001/jamanetworkopen.2022.3821
15.
ChoiSYerneniRHealySGoyalMNeighborsCJ.Predictors of medication utilization for opioid use disorder among Medicaid-insured HIV patients in New York. Am J Addict. 2020;29(2):151-154. doi:10.1111/ajad.12998
16.
WyseJJRobbinsJLMcGinnisKA, et al. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug Alcohol Depend. 2019;198:70-75. doi:10.1016/j.drugalcdep.2019.01.038
17.
LeeJDNunes EvJrNovoP, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2017;391(10118):309-318. doi:10.1016/S0140-6736(17)32812-X
18.
KorthuisPTCookRRLumPJ, et al. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. Addiction. 2022;117(7):1961-1971. doi:10.1111/add.15836
19.
LucasGMChaudhryAHsuJ, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med. 2010;152(11):704-711. doi:10.7326/0003-4819-152-11-201006010-00003
20.
MenzaTWHixsonLKLipiraLDrachL.Social determinants of health and care outcomes among people with HIV in the United States. Open Forum Infect Dis. 2021;8(7):ofab330. doi:10.1093/ofid/ofab330
21.
SimonCBTsuiJIMerrillJOAdwellATamruEKleinJW.Linking patients with buprenorphine treatment in primary care: Predictors of engagement. Drug Alcohol Depend. 2017;181:58-62. doi:10.1016/j.drugalcdep.2017.09.017
22.
ManhapraAStefanovicsERosenheckR.Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?Subst Abuse. 2020;41(1):110-120. doi:10.1080/08897077.2019.1640831
23.
PiskeMZhouHMinJE, et al. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. Addiction. 2020;115(8):1482-1493. doi:10.1111/add.14947
24.
EnglanderHKingCNicolaidisC, et al. Predictors of opioid and alcohol pharmacotherapy initiation at hospital discharge among patients seen by an inpatient addiction consult service. J Addict Med. 2020;14(5):415-422. doi:10.1097/adm.0000000000000611
25.
McLaughlinMFLiRCarreroNDBainPAChatterjeeA.Opioid use disorder treatment for people experiencing homelessness: A scoping review. Drug Alcohol Depend. 2021;224:108717. doi:10.1016/j.drugalcdep.2021.108717
26.
CantoneREGarveyBO’NeillA, et al. Predictors of medication-assisted treatment initiation for opioid use disorder in an interdisciplinary primary care model. J Am Board Fam Med. 2019;32(5):724-731. doi:10.3122/jabfm.2019.05.190012
27.
EgerWHAlticeFLLeeJ, et al. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder. Harm Reduct J. 2022;19(1):120. doi:10.1186/s12954-022-00703-8
28.
ShokoohiMBauerGRKaidaA, et al. Patterns of social determinants of health associated with drug use among women living with HIV in Canada: a latent class analysis. Addiction. 2019;114(7):1214-1224. doi:10.1111/add.14566
29.
EastwoodBStrangJMarsdenJ.Change in alcohol and other drug use during five years of continuous opioid substitution treatment. Drug Alcohol Depend. 2019;194:438-446. doi:10.1016/j.drugalcdep.2018.11.008
30.
FrostMCLampertHTsuiJIIles-ShihMDWilliamsEC.The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review. Addict Sci Clin Pract. 2021;16(1):62. doi:10.1186/s13722-021-00266-2
31.
NicholsCKunkelLEBakerR, et al. Use of single IRBs for multi-site studies: a case report and commentary from a National Drug Abuse Treatment Clinical Trials Network study. Contemp Clin Trials Commun. 2019;14:100319. doi:10.1016/j.conctc.2019.100319
HodderSLFeinbergJStrathdeeSA, et al. The opioid crisis and HIV in the USA: deadly synergies. Lancet. 2021;397(10279):1139-1150. doi:10.1016/s0140-6736(21)00391-3
34.
GodleyBAAdimoraAA.Syndemic theory, structural violence and HIV among African-Americans. Curr Opin HIV AIDS. 2020;15(4):250-255. doi:10.1097/coh.0000000000000634
35.
PerlmanDCJordanAE.The syndemic of opioid misuse, overdose, HCV, and HIV: structural-level causes and interventions. Curr HIV/AIDS Rep. 2018;15(2):96-112. doi:10.1007/s11904-018-0390-3
36.
BleasdaleJLeoneLAMorseGDLiuYTaylorSPrzybylaSM.Socio-structural factors and HIV care engagement among people living with HIV during the COVID-19 pandemic: a qualitative study in the United States. Trop Med Infect Dis. 2022;7(10):259. doi:10.3390/tropicalmed7100259
37.
SpearsCETaylorBSLiuAYLevySMEatonEF.Intersecting epidemics: the impact of coronavirus disease 2019 on the HIV prevention and care continua in the United States. AIDS. 2022;36(13):1749-1759. doi:10.1097/qad.0000000000003305
38.
BeltranRMHollowayIWHongC, et al. Social Determinants of disease: HIV and COVID-19 experiences. Curr HIV/AIDS Rep. 2022;19(1):101-112. doi:10.1007/s11904-021-00595-6
39.
ToweVLWiewelEWZhongYLinnemayrSJohnsonRRojasJ.A randomized controlled trial of a rapid re-housing intervention for homeless persons living with HIV/AIDS: Impact on housing and HIV medical outcomes. AIDS Behav. 2019;23(9):2315-2325. doi:10.1007/s10461-019-02461-4
MooreKERobertsWReidHHSmithKMZOberleitnerLMSMcKeeSA.Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abuse Treat. 2019;99:32-43. doi:10.1016/j.jsat.2018.12.003
42.
HohmannLPhillippeHMarloweK, et al. A state-wide education program on opioid use disorder: influential community members’ knowledge, beliefs, and opportunities for coalition development. BMC Public Health. 2022;22(1):886. doi:10.1186/s12889-022-13248-z
43.
LaudetAHarrisKKimballTWintersKCMobergDP.Collegiate recovery communities programs: what do we know and what do we need to know?J Soc Work Pract Addict. 2014;14(1):84-100. doi:10.1080/1533256x.2014.872015
ButkusRRappKCooneyTGEngelLS.Envisioning a better U.S. health care system for all: reducing barriers to care and addressing social determinants of health. Ann Intern Med. 2020;172(2 Suppl):S50-s59. doi:10.7326/m19-2410
46.
DoverDCBelonAP.The health equity measurement framework: a comprehensive model to measure social inequities in health. Int J Equity Health. 2019;18(1):36. doi:10.1186/s12939-019-0935-0
47.
LucykKMcLarenL.Taking stock of the social determinants of health: a scoping review. PLoS One. 2017;12(5):e0177306. doi:10.1371/journal.pone.0177306
48.
HansenHJordanAPloughAAlegriaMCunninghamCOstrovskyA.Lessons for the opioid crisis-integrating social determinants of health into clinical care. Am J Public Health. 2022;112(S2):S109-s111. doi:10.2105/ajph.2021.306651
49.
LeeCSLiebschutzJMAndersonBJSteinMD.Hospitalized opioid-dependent patients: exploring predictors of buprenorphine treatment entry and retention after discharge. Am J Addict. 2017;26(7):667-672. doi:10.1111/ajad.12533
50.
SwartzNAdnanTPeréaFBaggettTPChatterjeeA.Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness. J Subst Abuse Treat. 2022;138:108752. doi:10.1016/j.jsat.2022.108752
51.
KrahnJCaineVChaw-KantJSinghAE.Housing interventions for homeless, pregnant/parenting women with addictions: a systematic review. J Soc Distress Homeless. 2018;27(1):75-88. doi:10.1080/10530789.2018.1442186
52.
TutenMDeFulioAJonesHEStitzerM.Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification. Addiction. 2012;107(5):973-982. doi:10.1111/j.1360-0443.2011.03750.x
53.
Parlier-AhmadABRadicMSvikisDSMartinCE.Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender. Drug Alcohol Depend. 2022;232:109337. doi:10.1016/j.drugalcdep.2022.109337
54.
WyseJJMcGinnisKAEdelmanEJ, et al. Twelve-month retention in opioid agonist treatment for opioid use disorder among patients with and without HIV. AIDS Behav. 2022;26(3):975-985. doi:10.1007/s10461-021-03452-0
55.
SalonerBWhitleyPLaRueLDawsonEHuskeyA.Polysubstance use among patients treated with buprenorphine from a national urine drug test database. JAMA netw Open. 2021;4(9):e2123019-e2123019. doi:10.1001/jamanetworkopen.2021.23019
56.
CiceroTJEllisMSKasperZA.Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244-250. doi:10.2105/ajph.2019.305412
57.
GrovCWestmorelandDMorrisonCCarricoAWNashD.The crisis we are not talking about: one-in-three annual HIV seroconversions among sexual and gender minorities were persistent methamphetamine users. J Acquir Immune Defic Syndr. 2020;85(3):272-279. doi:10.1097/qai.0000000000002461
58.
StricklandJCStoopsWWDunnKESmithKEHavensJR.The continued rise of methamphetamine use among people who use heroin in the United States. Drug Alcohol Depend. 2021;225:108750. doi:10.1016/j.drugalcdep.2021.108750
59.
TrivediMHWalkerRLingW, et al. Bupropion and naltrexone in methamphetamine use disorder. New Engl J Med. 2021;384(2):140-153. doi:10.1056/NEJMoa2020214
60.
De CrescenzoFCiabattiniMD’AlòGL, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis. PLoS Med. 2018;15(12):e1002715. doi:10.1371/journal.pmed.1002715
61.
TaylorJLJohnsonSCruzRGrayJRSchiffDBagleySM.Integrating harm reduction into outpatient opioid use disorder treatment settings : harm reduction in outpatient addiction treatment. J Gen Intern Med. 2021;36(12):3810-3819. doi:10.1007/s11606-021-06904-4
62.
StackEHildebranCLeichtlingG, et al. Peer recovery support services across the continuum: In community, hospital, corrections, and treatment and recovery agency settings – a narrative review. J Addict Med. 2022;16(1):93-100. doi:10.1097/adm.0000000000000810
63.
SusukidaRCrumRMStuartEAEbnesajjadCMojtabaiR.Assessing sample representativeness in randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network. Addiction. 2016;111(7):1226-1234. doi:10.1111/add.13327
64.
McPhersonSBarbosa-LeikerCBurnsGLHowellDRollJ.Missing data in substance abuse treatment research: current methods and modern approaches. Exp Clin Psychopharmacol. 2012;20(3):243-250. doi:10.1037/a0027146
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
